Beta Bionics, Inc.(BBNX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,514 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in BBNX
Events flagged as statistical outliers against BBNX's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-07-30
BBNX quality score jumped 10 points (23→33) on a new filing
View source filing →
BBNX Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Beta Bionics, Inc. (BBNX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BBNX at 29.8/100 on a 32-signal composite quality model, placing it at rank #2,514 of 2,962 stocks — the bottom half of the AI-ranked universe. BBNX scores in the top quartile across revenue growth (88.0). Areas of concern include free cash flow (9.2) and balance sheet strength (9.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Beta Bionics, Inc. reports quarterly revenue of $32.0M, net income of $-23.4M, an operating margin of -79.9%. Top institutional holders of BBNX by reported 13-F value include EVENTIDE ASSET MANAGEMENT, Soleus Capital Management, L.P., MORGAN STANLEY, based on the most recent SEC filings. BBNX trades on the Nasdaq exchange and files with the SEC under CIK 1674632. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BBNX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Beta Bionics, Inc. directly from SEC EDGAR. Beta Bionics, Inc.'s 13F Pro composite quality score has ranged between 29 and 33 since 2025, currently 29.8 — a stable long-term trajectory across 50 quarterly and live scoring snapshots.
Revenue
Q2 2026
$32.0M
Net Income
Q2 2026
$-23.4M
Free Cash Flow
Q2 2026
$-15.7M
Operating Margin
Q2 2026
-79.9%
ROIC
Q2 2026
-39.9%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+53.9% YoYNet Income
-33.7% YoYOperating Income
-58.4% YoYEPS (Diluted)
+79.0% YoYTotal Assets
+119.7% YoYOp. Cash Flow
-5.5% YoYFree Cash Flow
-8.8% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $100.3M +53.9% | $65.1M +442.9% | $12.0M | — |
| Net Income | $-73.2M -33.7% | $-54.8M -24.2% | $-44.1M | — |
| Operating Income | $-71.7M -58.4% | $-45.3M -26.2% | $-35.9M | — |
| EPS (Diluted) | $-1.81 +79.0% | $-8.60 -3.5% | $-8.31 | — |
| Total Assets | $328.7M +119.7% | $149.6M +36.0% | $110.0M | — |
| Operating Cash Flow | $-50.9M -5.5% | $-48.3M -48.8% | $-32.4M | — |
| Free Cash Flow | $-56.2M -8.8% | $-51.7M -57.3% | $-32.8M | — |
Get alerted when BBNX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Beta Bionics, Inc. including:
Top Institutional Holders of BBNX
EVENTIDE ASSET MANAGEMENT, LLC
$98.1M6,253,673 shSoleus Capital Management, L.P.
$68.8M4,393,714 shMORGAN STANLEY
$66.9M4,266,822 shSands Capital Ventures, LLC
$58.1M3,708,043 shBlackRock, Inc.
$52.3M3,340,171 shPoint72 Asset Management, L.P.
$35.3M2,254,683 shVANGUARD CAPITAL MANAGEMENT LLC
$27.9M1,782,346 shVestal Point Capital, LP
$25.1M1,600,000 shRTW INVESTMENTS, LP
$23.5M1,500,000 shDEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$20.7M1,324,000 sh
| Fund | Value | Shares |
|---|---|---|
| EVENTIDE ASSET MANAGEMENT, LLC | $98.1M | 6,253,673 |
| Soleus Capital Management, L.P. | $68.8M | 4,393,714 |
| MORGAN STANLEY | $66.9M | 4,266,822 |
| Sands Capital Ventures, LLC | $58.1M | 3,708,043 |
| BlackRock, Inc. | $52.3M | 3,340,171 |
| Point72 Asset Management, L.P. | $35.3M | 2,254,683 |
| VANGUARD CAPITAL MANAGEMENT LLC | $27.9M | 1,782,346 |
| Vestal Point Capital, LP | $25.1M | 1,600,000 |
| RTW INVESTMENTS, LP | $23.5M | 1,500,000 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | $20.7M | 1,324,000 |
Companies Similar to BBNX
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
NeuroPace Inc
KESTRA MEDICAL TECHNOLOGIES, LTD.
UroGen Pharma Ltd.
Syndax Pharmaceuticals Inc
SS Innovations International, Inc.
CERUS CORP
PROCEPT BioRobotics Corp
EXAGEN INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put BBNX on your watchlist
Track score changes the day Beta Bionics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BBNX a good stock to buy?
13F Pro's AI-powered analysis of Beta Bionics, Inc. (BBNX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BBNX are available on the BBNX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BBNX is classified as a small company.
Which hedge funds own BBNX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BBNX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Beta Bionics, Inc.'s investment landscape.